A 2022 SS-31 as a mitochondrial protectant in the treatment of tendinopathy: evaluation in a murine supraspinatus tendinopathy model
fbioe-09-677576 April 24, 2021 Time: 18:16 # 1 BRIEF RESEARCH REPORT published: 29 April 2021 doi: 10.3389/fbioe.2021.677576 Edited by: Zhen Li, AO Research Institute, Switzerland Reviewed by: Guangli Suo, Suzhou Institute of Nano-tech and Nano-bionics (CAS), China Guang Yang, University of Maryland, College Park, United States *Correspondence: Hang Lin [email protected] These authors have contributed equally to this work and share rst authorship Specialty section: This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology Received: 07 March 2021 Accepted: 12 April 2021 Published: 29 April 2021 Citation: Huang Y, He Y, Makarcyzk MJ and Lin H (2021) Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Deng Y, Guo M, Zhou L, Huang Y, Srivastava S, Kumar A, Liu JQ (2024) Prospects, advances and biological applications of MOF-based platform for the treatment of lung cancer
Minor side effects, such as bruising at the injection site or mild vein irritation, are common but temporary
Pricing Clarity: Detailed pricing simplifies budgeting
